Ezetimibe (Ezetrol®);Ezétimibe (Ezetrol®)

Revue Medicale de Liege

Volumn 59, Issue 4, 2004, Pages 246-250

  Scheen, A J ^a,b  

^a UNIVERSITY OF LIÈGE   (Belgium)

^b UNIVERSITY OF LIÈGE   (Belgium)

Author keywords

Atherosclerosis; Cardiovascular disease; Cholesterol absorption; Ezetimibe; Hypercholesterolaemia; Statin

Indexed keywords

ANTILIPEMIC AGENT; CHOLESTEROL; EZETIMIBE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PHYTOSTEROL; AZETIDINE DERIVATIVE; HYPOCHOLESTEROLEMIC AGENT;

ATHEROSCLEROSIS; BELGIUM; CHOLESTEROL SYNTHESIS; DIET THERAPY; DOSE RESPONSE; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG INDICATION; DRUG MECHANISM; DRUG TOLERABILITY; FAMILIAL HYPERCHOLESTEROLEMIA; HYPERCHOLESTEROLEMIA; INTESTINE ABSORPTION; MORBIDITY; MORTALITY; REVIEW; ARTICLE; CARDIOVASCULAR DISEASE; DRUG COMBINATION; GENETICS; HUMAN; METABOLISM; TREATMENT OUTCOME;

ANTICHOLESTEREMIC AGENTS; AZETIDINES; CARDIOVASCULAR DISEASES; CHOLESTEROL; DRUG THERAPY, COMBINATION; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; PHYTOSTEROLS; TREATMENT OUTCOME;

EID: 2942668241     PISSN: 00353663     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (30)

1. Scheen AJ.- Le risque cardio-vasculaire lié à l'hypercholestérolémie: d'un continuum à la notion de normalité, de seuil d'intervention et d'objectif thérapeutique. Rev Med Liège, 1999, 54, 17-21.
2. Ito M, Delucca G, Aldridge M.- The relationship between low-density lipoprotein cholesterol goal attainment and prevention of coronary heart disease-related events. J Cardiovasc Pharmacol Ther, 2001, 6, 129-135.
3. Jacobson TA.- "The lower the better" in hypercholesterolemia therapy: a reliable clinical guideline? Ann Intern Med, 2000, 133, 549-554.
4. Scheen AJ, Kulbertus H.- "REVERSAL" et "PROVEIT": confirmation du concept « the lower, the better » dans le traitement de l'hypercholestérolémie chez le patient coronarien. Rev Med Liège, 2004, 59, 167-173.
5. Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults.- Executive Summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA, 2001, 285, 2486-2497.
6. DeBacker G, Ambrosioni E, Borch-Johnsen K, et al.- Executive Summary. European guidelines on cardiovascular disease prevention in clinical practice. Third Joint Task Force of European and other Societies on cardiovascular disease prevention in clinical practice. Eur Heart J, 2003, 24, 1600-1609.
7. Law MR, Wald NJ, Rudnicka AR.- Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis. BMJ, 2003, 326, 1423-1427.
8. Scheen AJ, Kulbertus H.- Prévention cardio-vasculaire par les statines: faut-il encore doser le cholestérol? Rev Med Liège, 2003, 58, 191-197.
9. Scheen A.- Le traitement des hyperlipidémies. Rev Med Liège, 1992, 47, 169-184.
10. Scheen AJ.- Les statines: du récepteur LDL à la protection cardio-vasculaire. Rev Med Liège, 1996, 51, 95-99.
11. Knopp R.- Drug treatment of lipid disorders. N Engl J Med, 1999, 341, 498-511.
12. Scheen AJ.- Comment je traite... Certaines maladies métaboliques grâce à une intervention pharmacologique ciblée sur l'intestin. Rev Med Liège, 1998, 53, 646-650.
13. Leitersdorf E.- Selective cholesterol absorption inhibition. A novel strategy in lipid-lowering management. Int J Clin Pract, 2002, 56, 116-119.
14. Bays H.- Ezetimibe. Expert Opin Invest Drugs, 2002, 11, 1587-1604.
15. Ezetimibe Supplement.- Evolving concepts: the role of ezetimibe in the management of hypercholesterolemia. Eur Heart J, 2002, 4 (Suppl J), J1-J22.
16. Sudhop T, Lütjohann D, Kodal A, et al.- Inhibition of intestinal cholesterol absorption by ezetimibe in humans. Circulation, 2002, 106, 1943-1948.
17. Darkes MJM, Poole RM, Goa KL.- Ezetimibe. Am J Cardiovasc Drugs, 2003, 3, 67-76.
18. Bruckert E, Giral Ph, Tellier Ph.- Perspectives in cholesterol-lowering therapy. The role of ezetimibe, a new selective inhibitor of intestinal cholesterol absorption. Circulation, 2003, 107, 3124-3128.
19. Altmann SW, Davis HR, Zhu L, et al.- Niemann-Pick C1 like protein is critical for intestinal cholesterol absorption. Science, 2004, 303, 1201-1204.
20. Ezzet F, Krisna G, Wexler DB, et al.- A population pharmacokinetic model that describes multiple peaks due to enterohepatic recirculation of ezetimibe. Clin Ther, 2001, 23, 871-885.
21. Knopp RH, Gitter H, Truitt T, et al.- Effect of ezetimibe, a new cholesterol absorption inhibitor, on plasma lipids in patients with primary hypercholesterolemia. Eur Heart J, 2003, 24, 729-741.
22. Dujovne CA, Ettinger MP, McNeer JF, et al.- Efficacy and safety of a potent new selective cholesterol absorption inhibitor, ezetimibe, in patients with primary hypercholesterolemia. Am J Cardiol, 2002, 90, 1092-1097.
23. Gagné C, Bays HE, Weiss SR, et al.- Efficacy and safety of ezetimibe added to ongoing statin therapy for treatment of patients with primary hypercholesterolemia. Am J Cardiol, 2002, 90, 1084-1091.
24. Davidson MH, McGarry Th, Bettis R, et al.- Ezetimibe coadministered with simvastatin in patients with primary hypercholesterolemia. J Am Coll Cardiol, 2002, 40, 2125-2134.
25. Melani L, Mills R, Hassman D, et al.- Efficacy and safety of ezetimibe coadministered with pravastatin in patients with primary hypercholesterolemia: a prospective, randomized, double-blind trial. Eur Heart J, 2003, 24, 717-728.
26. Ballantyne C, Houri J, Notarbartolo A, et al.- Effect of ezetimibe coadministered with atorvastatin in 628 patients with primary hypercholesterolemia. Circulation, 2003, 107, 2409-2415.
27. Gagné C, Gaudet D, Bruckert E, et al.- Efficacy and safety of ezetimibe coadministered with atorvastatin or simvastatin in patients with homozygous familial hypercholesterolemia. Circulation, 2002, 105, 2469-2475.
28. Salen G, von Bergmann K, Kwiterovitch P, et al.- Ezetimibe is an effective treatment for homozygous sitosterolemia (abstract). Circulation, 2002, 106 (Suppl. II), II-185.
29. Bonetti PO, Lerman LO, Napoli C, Lerman A.- Statin effects beyond lipid lowering - are they clinically relevant? Eur Heart J, 2003, 24, 225-248.
30. Scheen AJ.- Pharmaco-économie des médicaments hypolipidémiants: analyse des facteurs influenqant le rapport coût/efficacité. Rev Med Liège, 1998, 53, 220-222.